Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Premium
Indulgence
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
Nifty needs to hold 11,100 for further upside: Gaurav Garg of CapitalVia
The likelihood of a short-covering move along with addition of fresh position exists only if Nifty breaches 11,200
Indian drug makers gear up to make Gilead's remdesivir for Covid-19 therapy
Domestic players will be free to price it; Dutch firm Mylan also to make the drug in India; no royalty for Gilead as yet
USFDA issues warning letter to Jubilant Life for Roorkee facility
The company did not provide any details about the issues raised by the USFDA in its warning letter
Jubilant Life: Getting back on track
Improvement in margins and lower debt should help increase net profits
Jubilant Life gets US regulator approval for anti-inflammatory drug
Jubilant Life Sciences has a total of 84 ANDAs for oral solids filed in the US
